General and Administrative (G&A) Expenses. G&A expenses were $4.5 million for the three-month period ended Sept. 30, 2025, compared to $5.0 million for the three-month period ended Sept. 30, 2024. The ...
Positive FDA feedback confirms clear clinical pathway for BX011 targeting S. aureus in Diabetic Foot Infections, building on Company’s prior ...
Presented initial data from Phase 1b study suggesting GT-02287 has a disease-slowing effect consistent with the preclinical models in vivo and the proposed mechanism of action Completed enrollment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback